The NIH's Innovation Grants to Nurture Initial Translational Efforts (IGNITE) program, under funding opportunity PAR-25-060, seeks applications to develop and validate model systems that facilitate neurotherapeutic discovery. This opportunity (R61/R33 grant mechanism) focuses on creating animal models and human/animal tissue ex vivo systems that accurately reflect the characteristics of specific neurological or neuromuscular disorders. By enhancing the translational relevance of these models, the program aims to support early-stage neurotherapeutic drug discovery efforts. Importantly, this funding opportunity does not allow for clinical trials.
Eligible projects should propose models that can meaningfully assess therapeutic efficacy, contributing to both preclinical and eventual clinical research. This aligns with the IGNITE program’s mission to advance early-stage exploratory work in neurotherapeutic development, potentially leading to therapies for neurological disorders. The R61 phase supports initial model development, while the R33 phase is intended for further validation of promising models that meet set milestones.
A broad range of applicants is eligible, including public and private higher education institutions, nonprofits, for-profit entities (excluding small businesses), government entities, tribal organizations, and certain community-based organizations. Minority-serving institutions, such as Hispanic-serving Institutions, HBCUs, and Tribally Controlled Colleges and Universities, are also eligible. Non-U.S. organizations may not apply directly, but foreign components are allowed within U.S.-based applications as per NIH policy.
The grant offers a maximum funding of $750,000 per project, with no cost-sharing required, making it accessible to a variety of applicants. The application deadline is October 20, 2027, allowing ample time for planning and submission, and the program will be archived on November 25, 2027.
This funding opportunity is designed for research institutions and organizations working on neurological and neuromuscular disorders, particularly those interested in advancing preclinical research through translationally relevant model systems. Applicants should refer to the full announcement on the NIH website for detailed application requirements and contact NIH Grants Information for additional assistance.
